Market Overview

Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock

Share:
Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock

The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James.

The Analyst

Raymond James' Steven Seedhouse initiated coverage of Gilead Sciences with a Strong Buy rating and $93 price target.

The Thesis

A rundown of each segment Gilead addresses paints a bullish picture for the stock, Seedhouse said in the initiation note. They include:

  • The HCV business, which should start showing signs of stability in the bottom half of 2018 and generate around $2.5 billion in revenue in a few years, Seedhouse said. The competitive threat from rival therapy Mavyret is "baked in" to the stock at current levels, he said. 
  • The HIV business needed to see a strong launch with Biktarvy, and that's what occurred, the analyst said. HIV sales could peak at more than $20 billion annually by 2024, according to Raymond James, which implies a 5-percent compounded annual growth rate from 2017's $14 billion.
  • Vemlidy for hepatitis B is performing well, although the pipeline is stale, Seedhouse said. Gilead could work on developing the HBV business in 2019 and beyond, he said. 
  • CAR-T could be a growth driver for decades, Seedhouse said. 
  • Key data readouts for Filgotinib in the bottom half of 2018 and beyond are expected to validate what could become a multibillion-dollar pipeline opportunity, according to Raymond James. 
  • The NASH pipeline isn't as impressive as other areas, as rival companies boast better datasets, the analyst said. Nevertheless, Seedhouse forecast a 60-percent chance of Gilead seeing success in its STELLAR 3/4 trials.
  • Gastric cancer is a "long shot," but investors are overlooking this area, the analyst said, adding that Gilead could see some success in its Phase 3 GAMMA-1 trial.

Price Action

Gilead Sciences shares were trading higher by 2.13 percent at $70.10 at the time of publication Thursday afternoon. 

Related Links:

With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline

Cramer: Gilead Is Dead Money

Latest Ratings for GILD

DateFirmActionFromTo
Dec 2020Credit SuisseMaintainsNeutral
Nov 2020Morgan StanleyReinstatesEqual-Weight
Oct 2020BMO CapitalMaintainsMarket Perform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: Biktarvy CARTAnalyst Color Health Care Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
NVDASusquehannaMaintains625.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com